Article Text
Statistics from Altmetric.com
Recently, a large pragmatic study in 459 primary care patients with IBS comparing treatment outcome after 8 weeks of a diet lowering the intake of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) instructed via a smartphone application (n=218) or the antispasmodic agent otilonium bromide (OB) (n=217) was published.1 Here, we report a genetic survey in this cohort.
Data of 390 patients were amenable for genetical analysis after quality control: 192 in the medication arm and 198 in the diet arm. Responder rate was significantly higher in the diet than in the OB group (72% vs 61%, p=0.0014). Response was defined as an improvement of IBS symptom severity score of at least 50 points.1
Genotype data were generated on peripheral blood DNA using Illumina Global Screening Array, and standard quality controls were applied including selection of European ancestry individuals.2 Single-nucleotide polymorphism (SNP) data were extracted from prespecified relevant …
Footnotes
Contributors Clinical trial protocol, execution and publication: KVdH, LB, JTa and FC. DNA extraction: JTo, KVdH and FC. Genetic analysis: TZ, AF and MD'A. Manuscript draft: LMB. Gene selection, data analysis, critical revision of the manuscript and table: all authors.
Funding LMB received funding through a Postdoc.Mobility grant from the Swiss National Research Foundation (grant number P500PM_206612). JTa received funding through Methusalem from KU Leuven (grant number METH/21/04). MD was supported in part by funds from the Spanish Ministry of Science and Innovation (MICINN, PID2020-113625RB). The DOMINO study was funded by the Belgian Health Care Knowledge Centre (grant number 16001).
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.